Introduction to the molecular structure formula and pharmacological characteristics of Ribociclib

Ribociclib is a targeted anti-tumor drug that is a selective cyclin-dependent kinase 4/6 (CDK4/6 CDK4/6) inhibitor. The chemical name is(2E)-N-{5-[(5-{[4-(1-Piperazinyl)phenyl]amino}pyridin-2-yl)amino]pyridin-2-yl}- 2-propenamide, the molecular formula is C23H30N8O, and the molecular weight is 434.54. Its molecular structure has multiple aromatic rings and amino substituents, which is conducive to forming a stable combination with the active site of the target enzyme, thereby achieving targeted inhibition.

Structurally, Riboxiclib has a typical aromatic amine and piperazine ring structure, where the piperazine ring helps enhance the affinity of the molecule to CDK4/6enzyme. In addition, the molecule contains two pyridine rings and an amide group, and these structures jointly participate in hydrogen bonding and hydrophobic interactions with the active site of the kinase, making it highly selective and effective inhibitory effect. Its molecular structure also confers good oral activity and bioavailability, which is an important basis for long-term targeted therapy.

Pharmacologically, Riboxiclib blocks Rb (retinoblastoma protein) is phosphorylated, thereby preventing cells from entering the S phase from the G1 phase. This mechanism effectively inhibits tumor cell proliferation, especially in breast cancer patients who are hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-). Riboxiclib is often used in combination with aromatase inhibitors such as letrozole to form an endocrine-targeted therapy for breast cancer.

In clinical use, Riboxiclib has good tolerability and efficacy, and its common adverse reactions include neutropenia, fatigue, nausea, and QT interval prolongation. Since its metabolism mainly relies on the CYP3A4 enzyme system, attention should be paid to drug-drug interactions during use. As a member of the CDK4/6 inhibitor family, Ribociclib is similar to Palbociclib (Palbociclib) and Abeciclib (Abemaciclib) has certain differences in dosage, tolerance and dosing frequency on the basis of similar mechanisms, providing multiple options for personalized breast cancer treatment.

Reference materials:https://us.kisqali.com/